The Spanish Medicines Agency withdraws a batch of Junifen and two of Ibuprofen Sandoz

The Spanish Agency for Medicines and Health Products (AEMPS) issued a statement two days ago He removed a batch of Junifen and two of Ibuprofen Sandoz.

Junifen, as many parents will know, is Ibuprofen with a brand, the other being a generic medicine. Both have been removed for containing a higher total yeast and yeast count than expected.

What are the affected batches

The lots you have removed are the following:

  • Lots G03 and G04 of the drug Ibuprofen Sandoz 40 mg / ml oral suspension (NR 65865, CN 651172).
  • Lot H28 of the drug Junifen 40 mg / ml oral suspension (NR 65526, CN 936492)

If you look at the concentration, both are medications that are rarely used with younger children because they are the ones that have a composition of 4%, compared to the usual and most used 2%. So if you always buy the presentations at 2% you don't have to look at the lot, because it doesn't affect you.

The majority will have been consumed

The lots of Ibuprofen Sandoz 40 mg / ml oral suspension have been sold since February 2013 and that of Junifen 40 mg / ml since last January, so it is very possible that in pharmacies there are hardly any drugs left in these lots and they are in the homes of the parents, where many will already be in the trash finished (well, in the trash months ago ...). Those who stay at home they should be taken to the pharmacy.

And the children who have taken it?

The contamination of the medicines is due to a yeast in an amount greater than what is required. At the clinical level it is not problematic, since it is a microorganism that is already a habitual flora of the environment and of the same human being. In addition, when administered orally, it is destroyed upon digestion.

Now en children or people who are immunocompromised, their intake may pose a risk to their health, and for that reason it has been decided to withdraw the lots and make a statement for the population.

Video: Approaches to the non-clinical development of advanced therapy medicinal products (May 2024).